SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/07/24 VOXX International Corp. 8-K:5,8,9 3/01/24 9:186K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 41K 2: EX-99.1 Miscellaneous Exhibit HTML 22K 4: R1 Document And Entity Information HTML 45K 6: XML IDEA XML File -- Filing Summary XML 11K 9: XML XBRL Instance -- voxx-20240301_htm XML 15K 5: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 69K Linkbases Document -- voxx-20240301 7: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K 8: ZIP XBRL Zipped Folder -- 0000950170-24-027699-xbrl Zip 17K
8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i March 01, 2024 |
i VOXX INTERNATIONAL CORPORATION
(Exact name of Registrant as Specified in Its Charter)
i Delaware |
i 0-28839 |
i 13-1964841 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
i 2351 J. Lawson Boulevard |
|
|||
i Orlando, i Florida |
|
i 32824 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: i (800) i 645-7750 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
i Class A Common Stock $.01 par value |
|
i VOXX |
|
i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported in the Company’s Form 8-K filed on October 4, 2023 (the “October Form 8-K”), Ms. Loriann Shelton assumed the role of Chief Financial Officer of the Company, in addition to her role of Senior Vice President/Chief Operating Officer, effective March 1, 2024, for a one-year term through February 28, 2025. Also, as previously reported in the October Form 8-K, effective March 1, 2024, Mr. Charles M. Stoehr has transitioned to the role of Senior Vice President and Treasurer, has resigned from the Board of Directors and will not be standing for re-election as a director at the Company’s Fiscal 2024 Annual Meeting of Shareholders.
Mr. Beat Kahli, effective March 1, 2024, has stepped down as President of the Company, but will continue to serve as Co-Vice Chairman of the Company’s Board of Directors.
Item 8.01 Other Events.
On March 6, 2024, the Company issued a press release announcing that the Company’s majority owned subsidiary, EyeLock LLC, had entered into a joint venture agreement with GalvanEyes Partners LLC to engage in a newly formed entity, BioCenturion LLC, to operate its biometrics business. Each of the members will contribute selected assets and liabilities to the joint venture with GalvanEyes controlling the day to day operations. All working capital needs and the funding of losses of the joint venture shall be borne by GalvanEyes for the first two years. Beat Kahli will serve as Chairman of the Board and Chief Executive Officer of BioCenturion and Allen Ibaugh, who previously served as both President of EyeLock and CEO of GalvanEyes, will be the President of BioCenturion. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished under Item 8.01, including Exhibit 99.1, shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
VOXX INTERNATIONAL CORPORATION |
|
|
|
|
Date: |
By: |
/s/ Loriann Shelton |
|
|
|
|
Loriann Shelton |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
2/28/25 | ||||
Filed on: | 3/7/24 | |||
3/6/24 | ||||
For Period end: | 3/1/24 | |||
10/4/23 | 8-K | |||
List all Filings |